Abstract
Guidelines regarding the treatment of depression during pregnancy were recently published by the American Psychiatric Association and the American College of Obstetricians and Gynecologists. We provide a commentary on these guidelines.
References
Yonkers KA, Wisner KL, Stewart DE, et al.: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009, 114:703–713.
Yonkers KA, Wisner KL, Stewart DE, et al.: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009, 31:403–413.
Tanne JH: GlaxoSmithKline told to pay family $2.5 m after jury finds paroxetine caused son’s heart defects. BMJ 2009, 339:b4266.
Gaynes BN, Gavin N, Meltzer-Brody S, et al.: Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ) 2005, 119:1–8.
O’Connor EA, Whitlock EP, Beil TL, Gaynes BN: Screening for depression in adult patients in primary care settings: a systematic evidence review. Ann Intern Med 2009, 151:793–803.
U.S. Preventive Services Task Force: Screening for depression in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 2009, 151:784–792.
Dimidjian S, Goodman S: Nonpharmacologic intervention and prevention strategies for depression during pregnancy and the postpartum. Clin Obstet Gynecol 2009, 52:498–515.
O’Mahen HA, Flynn HA: Preferences and perceived barriers to treatment for depression during the perinatal period. J Womens Health (Larchmt) 2008, 17:1301–1309.
Kim DR, Gonzalez J, O’Reardon JP: Pregnancy and depression: exploring a new potential treatment option. Curr Psychiatry Rep 2009, 11:443–446.
Disclosure
Dr. Kim has been lent a device for research purposes by and received a travel stipend from Neuronetics.
Dr. O’Reardon has received grant research support from AstraZeneca, Bristol-Myers Squibb, CeneRx Biopharma, Cyberonics, Eli Lilly and Company, the Magstim Company, Medtronic, Neuronetics, Pfizer, Sanofi-Aventis, and the NARSAD Foundation; has served as a consultant for Eli Lilly and Company; and is a member of the speakers’ bureau for Eli Lilly and Company and Bristol-Myers Squibb.
Dr. Epperson has served as a consultant for Wyeth and owns stock in Johnson & Johnson.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, D.R., O’Reardon, J.P. & Epperson, C.N. Guidelines for the Management of Depression During Pregnancy. Curr Psychiatry Rep 12, 279–281 (2010). https://doi.org/10.1007/s11920-010-0114-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-010-0114-x